First AD

Second AD

Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL 

Dr Davids: What is your general approach to navigating available treatment options in patients with newly diagnosed CLL?

In which patients do you consider fixed duration vs continuous BTKi therapy?

How do the presence of high-risk features (del17p, TP53 mutations) influence your treatment decision?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Chronic Lymphocytic Leukemia

 Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy. 

Video Series

EHA 2024: Updates in the Treatment of CLL   

Peer Exchange

Leading chronic lymphocytic leukemia specialists explore strategies for selecting initial treatments, weighing the merits of fixed-duration versus continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy for newly diagnosed patients. 